TY - JOUR
T1 - Comparison of automatic versus manual procedures for the quantification of dopamine D2 receptor availability using I-123-IBZM-SPECT
AU - Heinzel, Alexander
AU - Shali, Siamak Mohammadkhani
AU - Dafotakis, Manuel
AU - Verburg, Frederik A.
AU - Mottaghy, Felix M.
AU - Winz, Oliver H.
PY - 2015/11
Y1 - 2015/11
N2 - Introduction I-123-IBZM-SPECT is often used to differentiate between idiopathic Parkinson's syndrome and atypical parkinsonian syndromes. The aim of this study was to compare three different procedures to quantify the receptor availability of striatal dopamine D2 receptors. (a) Manual quantification performed using individually adjusted volume of interests sets (mVoi). (b) Automatic quantification applying the commercially available Hermes BRASS software (BRASS). (c) Automatic quantification applying the open-source software IBZM Toolbox (TBX).Materials and methods Using the three methods, we analyzed 100 scans. For the mVOI methods, three different investigators (two experienced, one inexperienced) carried out the analysis. We compared the different methods with each other and with the reference standard established by clinical follow-up. The diagnostic performance was assessed by calculating receiver-operating characteristic (ROC) curves.Results Correlation analyses resulted in the following: mVOI versus BRASS (r(2)=0.694) (P<0.005), mVOI versus TBX (r(2)=0.557) (P<0.005); BRASS versus TBX (r(2)=0.466) (P<0.005). We found a fair agreement for mVOI versus BRASS; slight agreement for mVOI versus TBX; and fair agreement for BRASS versus TBX. Moreover, we found a substantial agreement between the experienced investigators, but not with the inexperienced investigator in the case of mVOI. The ROC analysis shows the largest area under the ROC curve (Az=0.7295) for mVOI, followed by BRASS (Az=0.709) and TBX (Az=0.627).Conclusion In direct comparison, the manual quantification used by experienced observers shows the best results, although it does not differ significantly from the commercial Hermes BRASS software. Both are superior to TBX. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
AB - Introduction I-123-IBZM-SPECT is often used to differentiate between idiopathic Parkinson's syndrome and atypical parkinsonian syndromes. The aim of this study was to compare three different procedures to quantify the receptor availability of striatal dopamine D2 receptors. (a) Manual quantification performed using individually adjusted volume of interests sets (mVoi). (b) Automatic quantification applying the commercially available Hermes BRASS software (BRASS). (c) Automatic quantification applying the open-source software IBZM Toolbox (TBX).Materials and methods Using the three methods, we analyzed 100 scans. For the mVOI methods, three different investigators (two experienced, one inexperienced) carried out the analysis. We compared the different methods with each other and with the reference standard established by clinical follow-up. The diagnostic performance was assessed by calculating receiver-operating characteristic (ROC) curves.Results Correlation analyses resulted in the following: mVOI versus BRASS (r(2)=0.694) (P<0.005), mVOI versus TBX (r(2)=0.557) (P<0.005); BRASS versus TBX (r(2)=0.466) (P<0.005). We found a fair agreement for mVOI versus BRASS; slight agreement for mVOI versus TBX; and fair agreement for BRASS versus TBX. Moreover, we found a substantial agreement between the experienced investigators, but not with the inexperienced investigator in the case of mVOI. The ROC analysis shows the largest area under the ROC curve (Az=0.7295) for mVOI, followed by BRASS (Az=0.709) and TBX (Az=0.627).Conclusion In direct comparison, the manual quantification used by experienced observers shows the best results, although it does not differ significantly from the commercial Hermes BRASS software. Both are superior to TBX. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
KW - atypical parkinsonian syndromes
KW - Hermes BRASS
KW - IBZM SPECT
KW - IBZM Toolbox
KW - idiopathic Parkinson's syndrome
KW - manual quantification
U2 - 10.1097/MNM.0000000000000363
DO - 10.1097/MNM.0000000000000363
M3 - Article
C2 - 26230172
SN - 0143-3636
VL - 36
SP - 1120
EP - 1126
JO - Nuclear Medicine Communications
JF - Nuclear Medicine Communications
IS - 11
ER -